The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | Comparing ropeginterferon alfa-2b to anagrelide in ET: topline results of SURPASS-ET
Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, presents the topline results of the SURPASS-ET trial (NCT04285086), highlighting that ropeginterferon alfa-2b showed superiority over anagrelide in both primary and secondary endpoints in high-risk patients with essential thrombocythemia (ET) intolerant or resistant to hydroxyurea. The trial also demonstrated the favorable safety profile of ropeginterferon alfa-2b, with lower rates of severe treatment-emergent adverse events and discontinuations due to toxicities compared to those seen with anagrelide. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We’re very excited to have shared here at EHA in the plenary session the top-line results of the Phase III trial of Ropeginterferon alfa-2b versus anagrelide. This was in a second-line therapy for people with ET who were high risk, they had failed hydroxyurea due to resistance and intolerance. We showed that first Ropeg was superior to anagrelide in its primary endpoint which is a modified ELN response as it related to control of the blood counts, absence or control of both splenomegaly and symptoms, as well as an absence of vascular events...
We’re very excited to have shared here at EHA in the plenary session the top-line results of the Phase III trial of Ropeginterferon alfa-2b versus anagrelide. This was in a second-line therapy for people with ET who were high risk, they had failed hydroxyurea due to resistance and intolerance. We showed that first Ropeg was superior to anagrelide in its primary endpoint which is a modified ELN response as it related to control of the blood counts, absence or control of both splenomegaly and symptoms, as well as an absence of vascular events. We also saw in key secondary endpoints that there was a clear difference favoring Ropeg as it related to the number of vascular events, as well as improvement in molecular markers, such as a variant allele frequency, both with the JAK2 and with CALR. In terms of safety, this also favored Ropeg with a much lower level of grade three treatment-emergent adverse events, as well as discontinuations related to toxicities.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
